Genetic biomarker may predict nerve pain side effects associated with prostate cancer treatment

May 13, 2016, H. Lee Moffitt Cancer Center & Research Institute

Taxanes are a group of drugs commonly used to treat cancers of the breast, lung, ovary, or prostate, but its use can be limited by significant side effects. Researchers from Moffitt Cancer Center report prostate cancer patients who have a variation in the VAC14 gene are more susceptible to a side effect called peripheral neuropathy when treated with the taxane docetaxel.

Peripheral neuropathy is a common side effect of taxane treatment. Patients who suffer from this condition have damage to their and experience weakness, numbness and pain usually in their hands or feet and occasionally in other areas of the body. This can limit the use of an otherwise effective cancer treatment.

In a study published online May 3 in the journal Clinical Cancer Research, researchers analyzed the DNA of men who had castrate-resistant and participated in a randomized phase 3 clinical trial that included docetaxel in the . Out of 623 patients from the study, 50 (8.1%) experienced debilitating peripheral neuropathy.

The researchers examined the patients' DNA for genetic variations called single nucleotide polymorphisms (SNPs) that were associated with docetaxel-induced peripheral neuropathy. They discovered that a variation in the VAC14 gene was highly associated with the incidence of docetaxel-induced .

"The genetic variant of VAC14 identified in this study could be useful for understanding the mechanism of docetaxel-induced neuropathy and may be informative for avoiding docetaxel treatment in patients at elevated neuropathy risk," said Howard McLeod, Pharm.D., medical director of the DeBartolo Family Personalized Medicine Institute at Moffitt. "This also offers new drug development strategies to improve the outcomes for cancer patients."

Explore further: Taxane-induced neuropathy not tied to breast cancer outcome

Related Stories

Taxane-induced neuropathy not tied to breast cancer outcome

August 2, 2012
(HealthDay) -- For patients with operable breast cancer, peripheral neuropathy due to adjuvant taxane therapy does not correlate with improved outcomes, according to research published online July 30 in the Journal of Clinical ...

Nerve damage from chemo may affect cancer survivors for years

January 15, 2016
(HealthDay)—Many women who survive cancer have symptoms of chemotherapy-related nerve damage in their feet and hands years after treatment, a new study reveals.

Even after anti-androgen therapy, docetaxel remains useful in prostate cancer

January 11, 2016
A study presented at the 2016 Genitourinary Cancers Symposium shows that 40 percent of patients with castration-resistant metastatic prostate cancer (mCRPC) treated with docetaxel following abiraterone had at least 50 percent ...

Neurofeedback reduces pain, increases quality of life for cancer patients suffering from chemotherapy-induced neuropathy

March 11, 2016
A new study from The University of Texas MD Anderson Cancer Center evaluating the use of neurofeedback found a decrease in the experience of chronic pain and increase quality of life in patients with neuropathic pain.

Researchers identify gene variations that predict chemotherapy side effects

April 9, 2013
Seemingly benign differences in genetic code from one person to the next could influence who develops side effects to chemotherapy, a Mayo Clinic study has found. The study identified gene variations that can predispose people ...

YouTube videos on peripheral nerve pain may misguide patients

October 21, 2015
Researchers who combed YouTube for videos regarding peripheral neuropathy, or nerve damage that causes weakness, numbness, and pain in the hands and feet, found 200 videos, but only about half of them were from healthcare ...

Recommended for you

Biologists discover how pancreatic tumors lead to weight loss

June 20, 2018
Patients with pancreatic cancer usually experience significant weight loss, which can begin very early in the disease. A new study from MIT and Dana-Farber Cancer Institute offers insight into how this happens, and suggests ...

Researchers find 11 genes responsible for the spread of cancer

June 20, 2018
A groundbreaking discovery by University of Alberta researchers has identified previously-unknown therapeutic targets that could be key to preventing the spread of cancer.

'Kiss of death' cancer: How computational geeks may have uncovered a therapy for a deadly disease

June 19, 2018
It's called the 'kiss of death'. Triple negative breast cancer has no targeted drug therapy and, as such, the only hope for these patients is chemotherapy. Triple negative breast cancer is aggressive and deadly. Patients ...

Ovarian cancer cells switched off by 'unusual' mechanism

June 19, 2018
Scientists at the Ovarian Cancer Action Research Centre at Imperial College London have discovered a mechanism that deactivates ovarian cancer cells.

Team discovers gene mutations linked to pancreatic cancer

June 19, 2018
Six genes contain mutations that may be passed down in families, substantially increasing a person's risk for pancreatic cancer. That's according to Mayo Clinic research published in the June 19 edition of the JAMA. However, ...

Breast cancer could be prevented by targeting epigenetic proteins, study suggests

June 19, 2018
Researchers at the Princess Margaret Cancer Centre in Toronto have discovered that epigenetic proteins promote the proliferation of mammary gland stem cells in response to the sex hormone progesterone. The study, which will ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.